YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $209, which is approximately 33.55% ...

On Monday, Goldman Sachs raised the price target for Ascendis Pharma (NASDAQ:ASND) to $195 from $170, while keeping a Buy rating on the stock. This adjustment follows the U.S. Food ...

Ascendis Pharma’s (ASND) Palopegteriparatide is a once-daily PTH replacement therapy approved by the FDA and EMA and branded as Yorvipath. It's the only approved drug for HP, although it's not yet ...

GET MORE AI-GENERATED SIGNALS: November 10, 2024, 17:44 pm ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...